In contrast, the TRAVERSE study assessed ALLO316, an allogeneic Transcription Activator–Like Effector Nuclease gene-edited anti-CD70 CAR-T product, in 17 patients with pretreated advanced or metastatic ccRCC. Here, CD70 is linked to nonpapillary renal cell carcinoma.